Breaking News Instant updates and real-time market news.

ARDM

Aradigm

$5.24

0.04 (0.77%)

07:22
12/01/16
12/01
07:22
12/01/16
07:22

Aradigm says Pulmaquin 'safe,' 'well tolerated' in ORBIT-3, ORBIT-4 trials

Aradigm announced top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin, the company's investigational proprietary formulation of once daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. The ORBIT-3 and ORBIT-4 pivotal trials were identical in design except for a pharmacokinetics sub-study that was conducted in one of the trials. The primary endpoint in both ORBIT-3 and ORBIT-4 was an increase in the median time to first mild, moderate or severe pulmonary exacerbation. The key secondary efficacy endpoint in both trials was the frequency of PE's over the 48-week double-blind treatment period. In ORBIT-4 the median time to first mild, moderate or severe PE was 230 days in the Pulmaquin treatment group as compared to 163 days in the placebo group. This increase in the median time to first PE was statistically significant using non-stratified log-rank analysis. In the key secondary efficacy endpoint, there was a 37% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group. This result was statistically significant with a Hazard Ratio of Pulmaquin/placebo of 0.63 using non-stratified binomial regression. In ORBIT-3 the median time to first mild, moderate or severe PE was 221 days in the Pulmaquin treatment group as compared to 136 days in the placebo group. This increase in the median time to first PE was similar to ORBIT-4 but was not statistically significant using non-stratified log-rank analysis. In the key secondary efficacy endpoint, there was a 13% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group. This result was not statistically significant with a Hazard Ratio of Pulmaquin/placebo of 0.87 using non-stratified binomial regression. The analyses of combined data from both studies resulted in a statistically significant reduction in the number of PE's over the 48-week double-blind period, representing a 27% reduction in PE's over the period. When the additional analyses of combined data from both studies were conducted taking into account only PE's that were moderate or severe the median time to first PE in the Pulmaquin group was 302 days vs. placebo 198 days. There was also a statistically significant reduction in the number of moderate and severe PE's over the 48-week double-blind period using non-stratified analysis, representing a 33% reduction in PE's over the period. In each study, the treatment groups were stratified for gender, pre-trial frequency of exacerbations and smoking status. The Statistical Analysis Plan for the studies called for stratified analyses; however, since some strata were found to have no or very few subjects, both non-stratified and stratified analyses were conducted. The company believes that due to the limited number of subjects in some strata the non-stratified analyses are more appropriate as strata that are too small can produce highly unstable estimated treatment effects with potential outliers. Using the stratified analyses, the median time to first PE in ORBIT-3 was Pulmaquin: 221 days; placebo: 136 days; p=0.7681 and for ORBIT-4 was Pulmaquin: 230 days; placebo: 163 days; p=0.0885. Both studies demonstrated a statistically significant reduction in P. aeruginosa density at Day 28, the end of the first on-treatment period. For each study, the magnitude of this antibiotic effect remained persistent throughout all on-treatment periods. Pulmaquin was safe and well tolerated in both studies. There were no differences in the changes of lung function or symptoms of airway irritation between the Pulmaquin and placebo groups in the two studies. Overall, the incidence of all treatment emergent adverse events was similar between the Pulmaquin and placebo groups in both ORBIT-3 and ORBIT-4. In ORBIT-3 the rates of serious TEAEs were 30.6% with Pulmaquin and 25.3% with placebo while in ORBIT-4 the rates were 17.0% versus 28.6%. For each study, the randomization rate of Pulmaquin treated subjects to placebo was 2 to 1. There were 8 deaths in ORBIT-3 and 6 deaths in ORBIT-4; placebo: 4. None of the deaths was related to Pulmaquin or placebo. The most frequently observed treatment related TEAEs were of respiratory/thoracic/mediastinal nature and were reported in ORBIT-3 by 25.7% of subjects with Pulmaquin and in 21.1% of subjects with placebo, while the rates in ORBIT-4 were 16.5% with Pulmaquin versus 19.4% with placebo. After the completion of the 48-week double-blind period, both Pulmaquin and placebo treated patients were given the opportunity to receive Pulmaquin in a 28-day open label extension period. 89% of the patients who completed ORBIT-3 and 91% of the patients who completed ORBIT-4 enrolled in the extension period. The company also announced that it has received the final statistical analysis report from the two year inhalation carcinogenicity study in rats with Pulmaquin; there were no differences in the rate of observed tumors between the Pulmaquin and control groups. Aradigm has been granted orphan drug designation for Pulmaquin for non-CF BE in the U.S. In addition, FDA has designated Pulmaquin as a Qualified Infectious Disease Product. The QIDP designation is granted for treatment of non-CF BE patients with chronic lung infections with P. aeruginosa and made Pulmaquin eligible for Fast Track designation which was granted by the FDA in September 2014. Further data from the Phase 3 studies will be presented in future publications and medical meetings.

TODAY'S FREE FLY STORIES

HCLP

Hi-Crush Partners

$22.97

1.5705 (7.34%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Upgrade
Hi-Crush Partners rating change  »

Wunderlich upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

PAA

Plains All American

$30.57

-0.67 (-2.14%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Options
Plains All American call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 08

    Aug

  • 08

    Nov

12:25
02/22/17
02/22
12:25
02/22/17
12:25
General news
Euro$ interest rate futures stalled out »

Euro$ interest rate…

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$74.55

-1.55 (-2.04%)

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

, GM

General Motors

$37.86

0.05 (0.13%)

12:23
02/22/17
02/22
12:23
02/22/17
12:23
Periodicals
PSA Group targets up to $2.1B in cost savings from Opel deal, Reuters says »

Peugeot (PUGOY) parent…

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

GM

General Motors

$37.86

0.05 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SCOR

comScore

$24.42

0.12 (0.49%)

12:21
02/22/17
02/22
12:21
02/22/17
12:21
Conference/Events
comScore to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 24

    Feb

BA

Boeing

$175.52

-0.04 (-0.02%)

, LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

12:19
02/22/17
02/22
12:19
02/22/17
12:19
Periodicals
Key lawmaker: Trump jet competition 'doesn't make sense,' Bloomberg reports »

Speaking in a Bloomberg…

BA

Boeing

$175.52

-0.04 (-0.02%)

LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

$NSD

NASDAQ Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$119.46

-0.2 (-0.17%)

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 24

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

12:15
02/22/17
02/22
12:15
02/22/17
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY traded…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

, UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

12:14
02/22/17
02/22
12:14
02/22/17
12:14
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

KHC

Kraft Heinz

$94.87

-1.78 (-1.84%)

TJX

TJX

$76.00

-0.245 (-0.32%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$34.04

2.05 (6.41%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

CHS

Chico's

$14.93

0.635 (4.44%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

FSLR

First Solar

$36.62

1.78 (5.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 19

    Mar

INGIY

Ingenico

$16.94

0.02 (0.12%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Hot Stocks
Ingenico finalizes acquisition of TechProcess; terms not disclosed »

Ingenico Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

HCLP

Hi-Crush Partners

$23.05

1.65 (7.71%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Upgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

12:05
02/22/17
02/22
12:05
02/22/17
12:05
General news
Treasury's $13 B 2-year FRN reopening was mixed »

Treasury's $13 B…

NFX

Newfield Exploration

$39.62

-2.87 (-6.75%)

12:01
02/22/17
02/22
12:01
02/22/17
12:01
Options
Newfield Exploration puts active as shares fall on earnings »

Newfield Exploration puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Conference/Events
JPMorgan biotech/biopharma analysts hold an analyst/industry conference call »

SMid Biotech Analyst…

TWTR

Twitter

$16.33

-0.09 (-0.55%)

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Hot Stocks
Twitter director of finance David Bicknell resigns »

David Bicknell, director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

PSX

Phillips 66

$78.29

-0.7425 (-0.94%)

11:56
02/22/17
02/22
11:56
02/22/17
11:56
Options
Phillips 66 put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

11:54
02/22/17
02/22
11:54
02/22/17
11:54
Conference/Events
Dolby management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 28

    Mar

TREX

Trex Company

$66.58

-4.57 (-6.42%)

11:53
02/22/17
02/22
11:53
02/22/17
11:53
Conference/Events
Trex Company management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

P

Pandora

$13.08

-0.065 (-0.49%)

11:52
02/22/17
02/22
11:52
02/22/17
11:52
Conference/Events
Pandora management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

CARB

Carbonite

$19.65

0.05 (0.26%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Conference/Events
Carbonite management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

RP

RealPage

$34.35

-0.2 (-0.58%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Hot Stocks
RealPage announces new multi-year agreement with Morgan Properties »

RealPage announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.